China NT Pharma Group Company Limited (Stock Code: 1011) announced the termination of its previously disclosed subscription agreements for the issuance of convertible bonds under a general mandate. The agreements, initially detailed in an announcement dated 9 February 2026, have been nullified through termination agreements signed on 10 February 2026. Before termination, no bonds or bond certificates had been issued, and no payment was made by the subscribers.

According to the company, the termination has no material adverse impact on its business operations or financial position. Trading in China NT Pharma’s shares was halted from 9:03 a.m. on 10 February 2026 and resumed at 9:00 a.m. on 11 February 2026 following the release of the termination announcement.